

Juan Miguel Mosquera

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9415374/publications.pdf>

Version: 2024-02-01

74
papers

6,850
citations

185998

28
h-index

98622

67
g-index

77
all docs

77
docs citations

77
times ranked

10978
citing authors

#	ARTICLE	IF	CITATIONS
1	Fine-needle aspiration biopsy of growing teratoma syndrome as a diagnostic pitfall of metastatic adenocarcinoma. <i>Diagnostic Cytopathology</i> , 2022, 50, .	0.5	0
2	Extracellular Matrix in Synthetic Hydrogel-Based Prostate Cancer Organoids Regulate Therapeutic Response to EZH2 and DRD2 Inhibitors (<i>Adv. Mater.</i> 2/2022). <i>Advanced Materials</i> , 2022, 34, .	11.1	0
3	Serial ctDNA analysis predicts clinical progression in patients with advanced urothelial carcinoma. <i>British Journal of Cancer</i> , 2022, 126, 430-439.	2.9	15
4	RET Fusion-Positive Papillary Thyroid Cancers are Associated with a More Aggressive Phenotype. <i>Annals of Surgical Oncology</i> , 2022, , 1.	0.7	8
5	Comparative genomics of primary prostate cancer and paired metastases: insights from 12 molecular case studies. <i>Journal of Pathology</i> , 2022, 257, 274-284.	2.1	13
6	The genomic landscape of metastatic clear cell renal cell carcinoma after systemic therapy. <i>Molecular Oncology</i> , 2022, 16, 2384-2395.	2.1	5
7	ASO Visual Abstract: RET Fusion-Positive Papillary Thyroid Cancers are Associated with a More Aggressive Phenotype. <i>Annals of Surgical Oncology</i> , 2022, , 1.	0.7	0
8	Inhibition of FGF receptor blocks adaptive resistance to RET inhibition in <i>CCDC6-RET</i> -rearranged thyroid cancer. <i>Journal of Experimental Medicine</i> , 2022, 219, .	4.2	6
9	A multidisciplinary approach to optimize primary prostate cancer biobanking. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2022, 40, 271.e1-271.e7.	0.8	2
10	Tumor-immune microenvironment revealed by Imaging Mass Cytometry in a metastatic sarcomatoid urothelial carcinoma with a prolonged response to pembrolizumab.. <i>Cold Spring Harbor Molecular Case Studies</i> , 2022, 8, .	0.7	6
11	Chromatin profiles classify castration-resistant prostate cancers suggesting therapeutic targets. <i>Science</i> , 2022, 376, .	6.0	75
12	Identifying synergistic high-order 3D chromatin conformations from genome-scale nanopore concatemer sequencing. <i>Nature Biotechnology</i> , 2022, 40, 1488-1499.	9.4	46
13	Integration of whole-exome and anchored PCR-based next generation sequencing significantly increases detection of actionable alterations in precision oncology. <i>Translational Oncology</i> , 2021, 14, 100944.	1.7	10
14	Incorporating cytologic adequacy assessment into precision oncology workflow using telepathology: An institutional experience. <i>Cancer Cytopathology</i> , 2021, 129, 874-883.	1.4	4
15	Targeting the epichaperome as an effective precision medicine approach in a novel PML-SYK fusion acute myeloid leukemia. <i>Npj Precision Oncology</i> , 2021, 5, 44.	2.3	20
16	Circulating tumor cell heterogeneity in neuroendocrine prostate cancer by single cell copy number analysis. <i>Npj Precision Oncology</i> , 2021, 5, 76.	2.3	25
17	Functional comparison of exome capture-based methods for transcriptomic profiling of formalin-fixed paraffin-embedded tumors. <i>Npj Genomic Medicine</i> , 2021, 6, 66.	1.7	8
18	Validation of a Circulating Tumor <i>sc</i> DNA-Based <i>sc</i> Next-Generation Sequencing Assay in a Cohort of Patients with Solid tumors: A Proposed Solution for Decentralized Plasma Testing. <i>Oncologist</i> , 2021, 26, e1971-e1981.	1.9	11

#	ARTICLE	IF	CITATIONS
19	Distinct Classes of Complex Structural Variation Uncovered across Thousands of Cancer Genome Graphs. <i>Cell</i> , 2020, 183, 197-210.e32.	13.5	141
20	Neuroendocrine differentiation in usual-type prostatic adenocarcinoma: Molecular characterization and clinical significance. <i>Prostate</i> , 2020, 80, 1012-1023.	1.2	22
21	Common germline-somatic variant interactions in advanced urothelial cancer. <i>Nature Communications</i> , 2020, 11, 6195.	5.8	21
22	Contemporary Results and Clinical Utility of Renal Mass Biopsies in the Setting of Ablative Therapy: A single center experience. <i>Cancer Treatment and Research Communications</i> , 2020, 25, 100209.	0.7	3
23	Fusions involving BCOR and CREBBP are rare events in infiltrating glioma. <i>Acta Neuropathologica Communications</i> , 2020, 8, 80.	2.4	12
24	SLFN11 Expression in Advanced Prostate Cancer and Response to Platinum-based Chemotherapy. <i>Molecular Cancer Therapeutics</i> , 2020, 19, 1157-1164.	1.9	44
25	Next-generation sequencing of residual cytologic fixative preserved DNA from pancreatic lesions: A pilot study. <i>Cancer Cytopathology</i> , 2020, 128, 840-851.	1.4	6
26	Prostate Multiparametric Magnetic Resonance Imaging Features Following Partial Gland Cryoablation. <i>Urology</i> , 2020, 138, 98-105.	0.5	9
27	Adenomyoepithelial tumors of the breast: molecular underpinnings of a rare entity. <i>Modern Pathology</i> , 2020, 33, 1764-1772.	2.9	14
28	Integrative multiplatform molecular profiling of benign prostatic hyperplasia identifies distinct subtypes. <i>Nature Communications</i> , 2020, 11, 1987.	5.8	29
29	Circulating tumor DNA profile recognizes transformation to castration-resistant neuroendocrine prostate cancer. <i>Journal of Clinical Investigation</i> , 2020, 130, 1653-1668.	3.9	122
30	Performance Characteristics of a Targeted Sequencing Platform for Simultaneous Detection of Single Nucleotide Variants, Insertions/Deletions, Copy Number Alterations, and Gene Fusions in Cancer Genome. <i>Archives of Pathology and Laboratory Medicine</i> , 2020, 144, 1535-1546.	1.2	10
31	Upper tract urothelial carcinoma has a luminal-papillary T-cell depleted contexture and activated FGFR3 signaling. <i>Nature Communications</i> , 2019, 10, 2977.	5.8	140
32	Clinical features of neuroendocrine prostate cancer. <i>European Journal of Cancer</i> , 2019, 121, 7-18.	1.3	195
33	Cancer-Specific Thresholds Adjust for Whole Exome Sequencing-Based Tumor Mutational Burden Distribution. <i>JCO Precision Oncology</i> , 2019, 3, 1-12.	1.5	21
34	Integrative Molecular Analysis of Patients With Advanced and Metastatic Cancer. <i>JCO Precision Oncology</i> , 2019, 3, 1-12.	1.5	24
35	Genomic correlates of clinical outcome in advanced prostate cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 11428-11436.	3.3	839
36	Delta-like protein 3 expression and therapeutic targeting in neuroendocrine prostate cancer. <i>Science Translational Medicine</i> , 2019, 11, .	5.8	105

#	ARTICLE	IF	CITATIONS
37	Gynecologic Organ Involvement During Radical Cystectomy for Bladder Cancer: Is It Time to Routinely Spare the Ovaries?. <i>Clinical Genitourinary Cancer</i> , 2019, 17, e209-e215.	0.9	7
38	Genetic and Epigenetic Determinants of Aggressiveness in Cribriform Carcinoma of the Prostate. <i>Molecular Cancer Research</i> , 2019, 17, 446-456.	1.5	44
39	The Clinical Utility of the Genomic Prostate Score in Men with Very Low to Intermediate Risk Prostate Cancer. <i>Journal of Urology</i> , 2019, 202, 96-101.	0.2	4
40	Oncogenic Addiction to ERBB2 Signaling Predicts Response to Trastuzumab in Urothelial Cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2019, 17, 194-200.	2.3	6
41	Bone biopsy protocol for advanced prostate cancer in the era of precision medicine. <i>Cancer</i> , 2018, 124, 1008-1015.	2.0	42
42	Characterization of CD34-deficient myofibroblastomas of the breast. <i>Breast Journal</i> , 2018, 24, 55-61.	0.4	7
43	GENE-10. IDENTIFICATION OF MXRA5 AND DSP AS RELEVANT TARGETS IN INFILTRATING ASTROCYTOMAS: A WHOLE EXOME ANALYSIS AT A SINGLE INSTITUTION. <i>Neuro-Oncology</i> , 2018, 20, vi104-vi105.	0.6	0
44	Patient derived organoids to model rare prostate cancer phenotypes. <i>Nature Communications</i> , 2018, 9, 2404.	5.8	246
45	Upper tract urothelial carcinoma is non-basal and T-cell depleted.. <i>Journal of Clinical Oncology</i> , 2018, 36, 4525-4525.	0.8	1
46	Targeting the Epichaperome As an Effective Precision Medicine Approach in a Novel PML-SYK Fusion Acute Myeloid Leukemia. <i>Blood</i> , 2018, 132, 1435-1435.	0.6	1
47	Personalized <i>In Vitro</i> and <i>In Vivo</i> Cancer Models to Guide Precision Medicine. <i>Cancer Discovery</i> , 2017, 7, 462-477.	7.7	735
48	Aberrant Activation of a Gastrointestinal Transcriptional Circuit in Prostate Cancer Mediates Castration Resistance. <i>Cancer Cell</i> , 2017, 32, 792-806.e7.	7.7	61
49	Next-Generation Rapid Autopsies Enable Tumor Evolution Tracking and Generation of Preclinical Models. <i>JCO Precision Oncology</i> , 2017, 2017, 1-13.	1.5	30
50	SPOP mutation drives prostate neoplasia without stabilizing oncogenic transcription factor ERG. <i>Journal of Clinical Investigation</i> , 2017, 128, 381-386.	3.9	29
51	An emerging role for cytopathology in precision oncology. <i>Cancer Cytopathology</i> , 2016, 124, 167-173.	1.4	23
52	Characterization of the leiomyomatous variant of myofibroblastoma: a rare subset distinct from other smooth muscle tumors of the breast. <i>Human Pathology</i> , 2016, 58, 54-61.	1.1	13
53	Clonal evolution of chemotherapy-resistant urothelial carcinoma. <i>Nature Genetics</i> , 2016, 48, 1490-1499.	9.4	250
54	Development and validation of a whole-exome sequencing test for simultaneous detection of point mutations, indels and copy-number alterations for precision cancer care. <i>Npj Genomic Medicine</i> , 2016, 1, .	1.7	68

#	ARTICLE	IF	CITATIONS
55	Intracellular location of BRCA2 protein expression and prostate cancer progression in the Swedish Watchful Waiting Cohort. <i>Carcinogenesis</i> , 2016, 37, 262-268.	1.3	7
56	The Initial Detection and Partial Characterization of Circulating Tumor Cells in Neuroendocrine Prostate Cancer. <i>Clinical Cancer Research</i> , 2016, 22, 1510-1519.	3.2	117
57	Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer. <i>Nature Medicine</i> , 2016, 22, 298-305.	15.2	1,193
58	Clonal evaluation of prostate cancer foci in biopsies with discontinuous tumor involvement by dual ERG/SPINK1 immunohistochemistry. <i>Modern Pathology</i> , 2016, 29, 157-165.	2.9	31
59	Whole-Exome Sequencing of Metastatic Cancer and Biomarkers of Treatment Response. <i>JAMA Oncology</i> , 2015, 1, 466.	3.4	264
60	The Placental Gene PEG10 Promotes Progression of Neuroendocrine Prostate Cancer. <i>Cell Reports</i> , 2015, 12, 922-936.	2.9	216
61	Phenotypic characterization of circulating tumor cells (CTCs) from neuroendocrine prostate cancer (NEPC) and metastatic castration-resistant prostate cancer (mCRPC) patients to identify a novel diagnostic algorithm for the presence of NEPC.. <i>Journal of Clinical Oncology</i> , 2015, 33, 197-197.	0.8	4
62	ERG induces taxane resistance in castration-resistant prostate cancer. <i>Nature Communications</i> , 2014, 5, 5548.	5.8	96
63	The oestrogen receptor alpha-regulated lncRNA NEAT1 is a critical modulator of prostate cancer. <i>Nature Communications</i> , 2014, 5, 5383.	5.8	522
64	Diagnostic utility of MYC amplification and anti-MYC immunohistochemistry in atypical vascular lesions, primary or radiation-induced mammary angiosarcomas, and primary angiosarcomas of other sites. <i>Human Pathology</i> , 2014, 45, 709-716.	1.1	96
65	SPOP Mutations in Prostate Cancer across Demographically Diverse Patient Cohorts. <i>Neoplasia</i> , 2014, 16, 14-W10.	2.3	145
66	MYB-NFIB gene fusion in adenoid cystic carcinoma of the breast with special focus paid to the solid variant with basaloid features. <i>Human Pathology</i> , 2014, 45, 2270-2280.	1.1	79
67	Prostate cancer with Paneth cell-like neuroendocrine differentiation has recognizable histomorphology and harbors AURKA gene amplification. <i>Human Pathology</i> , 2014, 45, 2136-2143.	1.1	28
68	Epigenomic Alterations in Localized and Advanced Prostate Cancer. <i>Neoplasia</i> , 2013, 15, 373-IN5.	2.3	69
69	Concurrent AURKA and MYCN Gene Amplifications Are Harbingers of Lethal Treatment-Related Neuroendocrine Prostate Cancer. <i>Neoplasia</i> , 2013, 15, 1-IN4.	2.3	205
70	Recurrent <i>NCOA2</i> gene rearrangements in congenital/infantile spindle cell rhabdomyosarcoma. <i>Genes Chromosomes and Cancer</i> , 2013, 52, 538-550.	1.5	189
71	A phase II trial of the aurora kinase A inhibitor MLN8237 in patients with metastatic castrate resistant and neuroendocrine prostate cancer.. <i>Journal of Clinical Oncology</i> , 2013, 31, TPS5096-TPS5096.	0.8	5
72	Association of concurrent AURKA and MYCN amplification in primary prostate adenocarcinoma with the development of lethal neuroendocrine prostate cancer (NEPC).. <i>Journal of Clinical Oncology</i> , 2012, 30, 120-120.	0.8	0

#	ARTICLE	IF	CITATIONS
73	Identifying cancer mutations in neuroendocrine prostate cancer (NEPC) through massively parallel DNA sequencing of formalin-fixed paraffin-embedded (FFPE) tissue.. Journal of Clinical Oncology, 2012, 30, 110-110.	0.8	0
74	Targeted next-generation sequencing (NGS) of advanced prostate cancer (PCA) using formalin-fixed tissue.. Journal of Clinical Oncology, 2012, 30, 4649-4649.	0.8	0